Related Experiment Videos
Levocetirizine: the allergist's arsenal grows larger
R Matthew Bloebaum1, J Andrew Grant
1The University of Texas Medical Branch, Department of Internal Medicine, Allergy and Immunology Division, Medical Research Bldg. 8.104, 301 University Boulevard, Galveston, Texas 77555-1083, USA.
Expert Opinion on Pharmacotherapy
|June 24, 2004
Summary
Levocetirizine, a selective H(1)-histamine blocker, offers effective and safe treatment for allergic rhinitis and chronic urticaria. This antihistamine demonstrates ideal pharmacokinetic and pharmacodynamic properties with minimal side effects.
Area of Science:
- Pharmacology
- Allergy and Immunology
Background:
- Antihistamines are crucial for managing allergic conditions like allergic rhinitis and chronic urticaria.
- Selective H(1)-histamine blockers have been developed to minimize side effects associated with older antihistamines that cross the blood-brain barrier.
Purpose of the Study:
- To evaluate the efficacy and safety of levocetirizine as a selective H(1)-histamine blocker.
- To highlight the favorable pharmacokinetic and pharmacodynamic characteristics of levocetirizine.
Main Methods:
- Review of clinical trials investigating levocetirizine.
- Pharmacological and pharmacokinetic analysis of levocetirizine's properties.
Main Results:
- Levocetirizine demonstrated high bioavailability, rapid onset of action, and limited distribution.
- Clinical trials confirmed its safety and effectiveness in treating allergic rhinitis and chronic urticaria.
- Minimal adverse effects were observed, indicating a favorable safety profile.
Conclusions:
- Levocetirizine is an effective and safe H(1)-histamine blocker for allergic rhinitis and chronic urticaria.
- Its pharmacokinetic and pharmacodynamic profile aligns with the characteristics of an ideal antihistamine.
- Levocetirizine represents a valuable therapeutic option with a low incidence of untoward effects.